Warts - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 78 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Warts - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Warts - Pipeline Review, H2 2014', provides an overview of the Warts's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Warts, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Warts and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Warts
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Warts and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Warts products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Warts pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Warts
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Warts pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Warts Overview 8
Therapeutics Development 9
Pipeline Products for Warts - Overview 9
Pipeline Products for Warts - Comparative Analysis 10
Warts - Therapeutics under Development by Companies 11
Warts - Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Warts - Products under Development by Companies 15
Warts - Companies Involved in Therapeutics Development 16
Helix BioPharma Corp. 16
CEL-SCI Corporation 17
NanoViricides, Inc. 18
3M Drug Delivery Systems 19
G&E Herbal Biotechnology Co., Ltd. 20
Anaconda Pharma 21
Foamix Ltd. 22
BioMAS Ltd. 23
ViroStatics, srl 24
Cutanea Life Sciences 25
Burke Pharmaceuticals, LLC 26
Agilvax, Inc. 27
Nielsen Biosciences, Inc. 28
Warts - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Combination Products 30
Assessment by Target 31
Assessment by Mechanism of Action 34
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
interferon alpha-2b (recombinant) - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
AS-101 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
SRT-100 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
AP-611074 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Candida Albicans Antigen - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
(digoxin + furosemide) - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Leukocyte Interleukin - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
A-101 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
BURKE-201 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
AX-03 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
HerpeCide-I - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
imiquimod - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
854-A - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
PP-210 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Small Molecule to Inhibit CDK9 for HPV Associated Cancers and Warts - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Warts - Recent Pipeline Updates 59
Warts - Dormant Projects 70
Warts - Discontinued Products 71
Warts - Product Development Milestones 72
Featured News & Press Releases 72
Feb 12, 2014: Targeted Therapy for WHIM Syndrome Shows Promise NIAID study is the first to examine long-term use of plerixafor in any disease 72
Feb 03, 2014: U.S. Navy Approves Start of CEL-SCI's Phase I Trial for Treatment of Anal Warts in HIV/HPV Co-Infected Patients 72
Dec 18, 2013: Medigene's drug Veregen launched in Norway and Sweden 73
Jul 29, 2013: Medigene: Market launch of Veregen in the Netherlands started 74
Feb 26, 2013: Medigene Announces Inclusion Of Veregen In European Treatment Guideline For Management Of Anogenital Warts 74
Oct 26, 2012: South Africa, first to grant IP protection in anti-warts 75
Jan 05, 2011: CDC Recommends Nycomed's VEREGEN As Therapeutic Option For EGWs In 2010 STD Treatment Guidelines 75
Feb 25, 2010: Fougera Wins First Generic Approval For Imiquimod Cream 5% 76
Appendix 77
Methodology 77
Coverage 77
Secondary Research 77
Primary Research 77
Expert Panel Validation 77
Contact Us 78
Disclaimer 78

List of Tables
Number of Products under Development for Warts, H2 2014 9
Number of Products under Development for Warts - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Comparative Analysis by Clinical Stage Development, H2 2014 13
Comparative Analysis by Early Stage Development, H2 2014 14
Products under Development by Companies, H2 2014 15
Warts - Pipeline by Helix BioPharma Corp., H2 2014 16
Warts - Pipeline by CEL-SCI Corporation, H2 2014 17
Warts - Pipeline by NanoViricides, Inc., H2 2014 18
Warts - Pipeline by 3M Drug Delivery Systems, H2 2014 19
Warts - Pipeline by G&E Herbal Biotechnology Co., Ltd., H2 2014 20
Warts - Pipeline by Anaconda Pharma, H2 2014 21
Warts - Pipeline by Foamix Ltd., H2 2014 22
Warts - Pipeline by BioMAS Ltd., H2 2014 23
Warts - Pipeline by ViroStatics, srl, H2 2014 24
Warts - Pipeline by Cutanea Life Sciences, H2 2014 25
Warts - Pipeline by Burke Pharmaceuticals, LLC, H2 2014 26
Warts - Pipeline by Agilvax, Inc., H2 2014 27
Warts - Pipeline by Nielsen Biosciences, Inc., H2 2014 28
Assessment by Monotherapy Products, H2 2014 29
Assessment by Combination Products, H2 2014 30
Number of Products by Stage and Target, H2 2014 33
Number of Products by Stage and Mechanism of Action, H2 2014 35
Number of Products by Stage and Route of Administration, H2 2014 37
Number of Products by Stage and Molecule Type, H2 2014 39
Warts Therapeutics - Recent Pipeline Updates, H2 2014 59
Warts - Dormant Projects, H2 2014 70
Warts - Discontinued Products, H2 2014 71